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Background: Few serological tests are available for detecting antibodies against Mycoplasma capricolum subsp.
capripneumoniae, the causal agent of contagious caprine pleuropneumonia (CCPP). The complement fixation test,
the test prescribed for international trade purposes, uses a crude antigen that cross-reacts with all the other
mycoplasma species of the “mycoides cluster” frequently infecting goat herds. The lack of a more specific test has been
a real obstacle to the evaluation of the prevalence and economic impact of CCPP worldwide. A new competitive ELISA
kit for CCPP, based on a previous blocking ELISA, was formatted at CIRAD and used to evaluate the prevalence of CCPP
in some regions of Kenya, Ethiopia, Mauritius, Tajikistan and Pakistan in an international collaborative study.
Results: The strict specificity of the test was confirmed in CCPP-free goat herds exposed to other mycoplasma species of
the ‘’mycoides cluster”. Prevalence studies were performed across the enzootic range of the disease in Africa and Asia.
Seroprevalence was estimated at 14.6% in the Afar region of Ethiopia, whereas all the herds presented for
CCPP vaccination in Kenya tested positive (individual seroprevalence varied from 6 to 90% within each herd).
In Mauritius, where CCPP emerged in 2009, nine of 62 herds tested positive. In Central Asia, where the disease was
confirmed only recently, no positive animals were detected in the Wakhan District of Afghanistan or across the border
in neighboring areas of Tajikistan, whereas seroprevalence varied between 2.7% and 44.2% in the other districts
investigated and in northern Pakistan. The test was also used to monitor seroconversion in vaccinated animals.
Conclusions: This newly formatted CCPP cELISA kit has retained the high specificity of the original kit. It can
therefore be used to evaluate the prevalence of CCPP in countries or regions without vaccination programs. It
could also be used to monitor the efficacy of vaccination campaigns as high-quality vaccines induce high rates
of seroconversion.
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Contagious caprine pleuropneumonia (CCPP) has been
known as a clinical condition for 140 years [1], but the
burden and distribution of this disease remain largely
unknown. The causal agent of CCPP was first isolated in
1976 [2], but it was not given its species name until
1993: M. capricolum subsp. capripneumoniae (Mccp)
[3]. Conspicuous macroscopic lesions are observed in
animals with acute disease. These lesions are restricted
to the pleural cavity and consist of unilateral pleuro-
pneumonia with profuse pleural effusion, but diagnosis
may still be difficult. Until the development of specific
PCR assays [4,5], it was difficult to obtain laboratory
confirmation of CCPP. Autopsies are rarely performed
on goats dying from the disease and, when samples are
sent to the laboratory for isolation of the causal agent,
other mycoplasmas, such as M. mycoides subsp. capri
(Mmc), M. capricolum subsp. capricolum (Mcc) and
M. ovipneumoniae, are often isolated. This is due to the
extremely fastidious growth of Mccp, which is overgrown
by faster growing mycoplasmas. Furthermore, animals
are often treated with antibiotics, hampering isolation of
the causal agent. Despite great improvements in the for-
mulation of culture media, the isolation of Mccp remains
very difficult [6]. It was thought that the use of PCR for
the molecular detection of Mccp would greatly facilitate
the diagnosis of CCPP and provide more accurate infor-
mation about the prevalence of the disease.
However, there have been very few declarations of
CCPP outbreaks to the OIE in the last 15 years, due to a
lack of awareness of this disease and possible confusion
with other diseases, such as “peste des petits ruminants”
(PPR) or Pasteurella infections. Little is known about
the economic impact of CCPP, although participatory
epidemiological surveillance, without the need for la-
boratory confirmation, may prove a useful approach. For
example, Turkana pastoralists in Kenya rank CCPP as
one of the principal diseases affecting their goats, to-
gether with PPR and sarcoptic mange [7]. The impact of
CCPP and the potential threat represented by this dis-
ease have been greatly underestimated.
Until recently, CCPP was believed to be confined to
Africa and the Middle East. Its presence in Asia was
confirmed only recently, with the isolation of Mccp
strains in China [8] and the detection of Mccp by PCR
in Pakistan [9] and Tajikistan. Molecular epidemiology
studies have shown that the Mccp strains circulating in
Asia belong to a specific clade supported by significant
bootstrap values [10]. This indicates that the presence of
the disease in Asia is not the result of a recent introduc-
tion, which would have resulted in Asian Mccp geno-
types closely resembling genotypes found elsewhere.
Indeed, it was suggested that CCPP was present in India
as early as 1914 [11]. The disease was also recognized inthe European part of Turkey in 2005 [12] and poses a
threat to the Balkan countries of the European Union.
CCPP has been shown to infect wildlife species held in
captivity for conservation purposes in Qatar [13] but has
also been detected in free-ranging wildlife in Tibet [14].
This is a matter of concern not only for free-ranging en-
dangered species in which CCPP may occur [15], but
also for CCPP-free countries importing wild species for
propagation purposes or for zoological collections.
CCPP is difficult to control. The vaccines against
CCPP consist of inactivated Mccp antigen with saponin as
an adjuvant [16]. If effective, these vaccines should induce
marked seroconversion, and this need-s to be investigated
furher. The antibodies induced by vaccination can inter-
fere with the results of disease prevalence studies, but
cELISA could be used to assess the efficacy of vaccination
campaigns. Vaccination efficacy has been assessed in ex-
perimental trials, leading to the definition of an optimum
Mccp antigen concentration of 0.15 mg/dose, which yields
a protective immune response [17].
The lack of a reliable, commercially available specific
ELISA test for detecting Mccp antibodies was recog-
nized as a key issue during the design of an EU-funded
project aiming to control neglected animal diseases in
Africa through vaccination (VACNADA). A blocking
ELISA based on the use of a specific monoclonal antibody
recognizing Mccp was developed in 1994 [18]. This kit has
recently been modified to obtain a heat-stable kit produced
to quality assurance standards. We describe here the use of
this new kit to evaluate the prevalence of CCPP in various
countries and to evaluate the seroconversion induced by
the CCPP vaccine.
Methods
Formatting of the cELISA kit
The same components of the kit developed in 1994 [18]
were used, but the kit was modified in collaboration with
a private company, IDEXX-Montpellier SAS. The hy-
bridoma cell line “4.52” developed by CIRAD was revivi-
fied and subcloned to check its stability. The main
objective was then to produce stable precoated plates
and to design a protocol yielding results similar to those
originally reported, in terms of specificity and sensitivity.
Serum samples known to be positive and negative were
used to achieve this end.
The final CCPP cELISA kit protocol differed slightly
from the original published protocol, as it was a strict
competitive assay rather than a blocking assay. We mini-
mized the variability of incubation time by first mixing
diluted sera (1/10) with a fixed quantity of monoclonal
antibody in a normal non-coated plate and then trans-
ferring the mixture to a precoated plate and incubating
at 37°C for one hour, with gentle shaking. The plates
were then incubated for 30 minutes with the conjugate
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strate. Plates were washed manually between steps in the
protocol. The final protocol for the CCPP cELISA very
closely resembled that used for contagious bovine
pleuropneumonia testing (IDEXX-Montpellier 309 SAS,
ref: P05410-10).
Once the kit had been developed, a validation batch
was produced by IDEXX-Montpellier SAS (“beta kit”
CIRAD-Vacnada) and subjected to accelerated stability
testing by incubation at 37°C for 2 months, with testing
at various time points.
In this competitive ELISA, the final results are given
by the formula [(ODMab-ODTest)/(ODMab-ODconju-
gatecontrol)]*100 and are expressed as the “percentage
inhibition” (PI).
Whenever possible, the kit was validated according to
the rules laid down in chapter 1.1.5 of the OIE manual
of standards (http://www.oie.int/en/international-standard-
setting/terrestrial-manual/access-online/).
Determination of the cutoff point maximizing diagnostic
specificity
This cutoff point was established by analyzing 478 serum
samples from 16 goat herds from France, which is a
CCPP-free country. The status of each herd, in terms of
the circulation of mycoplasmas from the “Mycoides
cluster”, was determined before the study, by culturing
various samples, as previously described [19]. For each
herd, a bulk milk sample was collected, together with
individual milk. Seven herds were considered to be
mycoplasma-infected, because M. mycoides subsp. capri
(Mmc) or M. capricolum subsp. capricolum (Mcc) strains
were isolated from the bulk tank milk and/or from at least
one individual milk sample.
Quality assurance during testing
Once the cutoff point had been established, the confi-
dence interval around this value was established in the
CIRAD laboratory, taking several factors into account.
First, an “internal reference material” (IRM) serum with
a titer slightly higher than the cutoff point was produced
and freeze-dried. This IRM serum was tested on four
different occasions, by three technicians and at various
positions in the plates, with the generation of 392 results
in total.
All the ELISA tests were conducted in accordance
with the general guidelines of ISO17025 at CIRAD-
UMR15, which has obtained accreditation from the
French Committee for Accreditation for this cELISA test
(COFRAC certificate N° 1–2207).
Seroprevalence in Central Asia
The cELISA was used to investigate the presence of
CCPP in remote districts of Afghanistan, Pakistan andTajikistan centered on the Pamir mountain range. In each
country, two (Pakistan) or three (Afghanistan, Tajikistan)
sampling areas at least 50 km apart were selected,
to ensure broad geographical coverage (Figure 1). In
Afghanistan, 359 goats from eight sites in the district of
Wakhan, Badakhshan Province were selected. No clinical
cases of CCPP had been reported in these districts
(Ostrowski pers. obs. 2012). In Pakistan, 410 goats from six
sites in the Diamer and Gilgit districts, Gilgit-Baltistan
Province were sampled. Clinical cases of CCPP were re-
ported, but Mccp was never isolated (Ghulam Abbas pers.
comm. 2012) at these sites. In Tajikistan, 395 goats from
eight sites, including 196 from the Shuro-obod District,
Khatlon Province and Darvoz District, Gorno Badakhshan
Autonomous Oblast (Province) were sampled. Clinical
cases of CCPP occurred in 2008 and Mccp was detected
at these sites in 2010 [20] In addition, 199 goats from the
Ishkoshim and Murghob districts in Gorno Badakhshan
Autonomous Oblast, in which no clinical cases of CCPP
were reported, were also sampled.
Seroprevalence in infected countries in East Africa
and Mauritius
Serum samples were collected from Kenya, in the area
around Narok, 300 km west of Nairobi, where CCPP is
known to be enzootic. Herds were selected on the basis
of the willingness of their owners to participate in a vac-
cination campaign organized by the VACNADA project.
There was no evidence of clinical signs of CCPP in the
herds at the time of sampling. All animals from the
selected herds were sampled (10 herds, N = 895). In
Ethiopia, samples were obtained from the Afar region, in
which CCPP is known to have been present since its
introduction in 1990, in the eastern part of the country
[21]. One thousand serum samples were collected from
the Dubti and Hadar districts, from two sites per district
in which no vaccination had been performed during the
last five years. We sampled 75% of the herds, by select-
ing at random at least 20 serum samples per herd, from
animals that were at least two months old.
In addition, serum samples were also collected from
Mauritius, where CCPP has recently been identified
[22]. Sixty-two herds were selected to constitute a sam-
ple representative of the whole island and 10 to 15 adult
goats were randomly selected from each herd (62 herds,
N = 720).
Seroconversion in vaccinated animals
A reference batch of CCPP vaccine was produced by
CIRAD, as described by Rurangirwa [16], but with slight
modification of the published protocol, including inacti-
vation before freeze-drying. Briefly, the Mccp antigen
consisted of a four-day culture of the “Abomsa” strain.
The mycoplasmas were concentrated and washed three
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Figure 1 Map showing the countries and regions studied in the CCPP-cELISA serological survey. A: World map showing the various
locations. The green circle represents France, where the specificity of the test was validated, B: Central-Asian location around the Wakhan district
in Afghanistan, C: Afar depression in Ethiopia, D: Narok district in Kenya, E: Reunion Island; the dots indicate the locations of the sampled herds
that tested negative by CCPP cELISA, whereas the red starts indicate the locations of the sampled herds testing positive.
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washing with PBS. The concentrated suspension (1 mg/ml)
was inactivated by the binary ethylenimine procedure
[23,24] and freeze-dried. The inactivation process was
checked by culture. The protein content of each vial was
determined by the bicinchoninic acid method, with bovine
serum albumin as the reference. The saponin adjuvant was
prepared immediately before use, by dissolving saponin
powder (Sigma, ref. S4521, batch 010 M7015) to obtain the
desired amount per dose.
Six-year old naive goats were immunized at CIRAD
with a vaccine meeting OIE requirements: 0.15 mg of
antigen and 3 mg of saponin per dose. The immunization
protocol was approved by the local ethics committee and
the goats were housed in an animal facility controlled
by French veterinary services (certificate: C34-172-20).
Serum samples were collected at weekly intervals for two
months and then after five months. Various combinations
of antigen and saponin doses were then prepared andused to immunize goats at the African Union Pan African
Veterinary Vaccine Center (AU-PANVAC, Ethiopia).
Saponin-adjuvanted vaccines are registered in Ethiopia
and do not require specific authorization for use. The
animal facilities at AU-PANVAC are located within the
National Veterinary Institute, Debre-Zeit, which is the ref-
erence laboratory for vaccine production and quality
testing in Ethiopia. We tested the following ratios,
expressed in mg mycoplasma protein/mg saponin per dose:
A = 0.15/3; B = 0.15/0.3; C = 0.05/3; D = 0.05/0.3; E = 0/3;
F = 0.15/0. Sera were collected weekly for six weeks and
tested by cELISA.
Results
Kit performance
When the kit was stored at 37°C, the values for the con-
trol monoclonal antibody (Mab) declined over time.
They remained above the accepted limit (0.5 OD) for
three weeks, after which, the percentage inhibition (PI)
Peyraud et al. BMC Veterinary Research 2014, 10:48 Page 5 of 9
http://www.biomedcentral.com/1746-6148/10/48value obtained for the laboratory internal positive refer-
ence serum decreased slightly, from a mean of 61PI to
54PI, but clearly remained within acceptable limits.
Once the kit had been formatted and a preliminary
batch had been produced in an industrial production
process by IDEXX-Montpellier SAS, the specificity of
the test was assessed on 478 serum samples of French
origin of known infection status. The distribution of
results followed a Gaussian curve, with a mean PI of
25.5. There was no correlation between mean cELISA
titer and mycoplasma infection status. Indeed, Myco-
plasma mycoides subsp. capri (Mmc) was the most fre-
quently isolated mycoplasma species (six of the seven
herds for which infection was detected on the basis of
tests on milk), whereas Mycoplasma capricolum subsp.
capricolum (Mcc) was detected only once. The 40 serum
samples with the highest titers, including two individ-
ual serum samples with PI values of 56 and 57, were
retested twice, to determine the titer more precisely. The
highest mean PI value for a negative serum was 54. A
cutoff point of 55PI was applied, so the test was strictly
specific.
An internal reference serum, with a titer close to the
cutoff point, was tested in 392 replicates, on four differ-
ent dates, by three technicians. All the results were
pooled and the distribution was evaluated. The curve
obtained was strictly Gaussian, with a mean PI value of
56. The standard deviation (SD) of this mean was 3.5.
Further testing over a one-year period showed the un-
certainty of measurement around the mean to be 8PI for
serum samples with titers around the cutoff point. This
uncertainty was estimated taking into account all the re-
agents, equipment and parameters critical for a cELISA
test, as specified by the ISO-17025 standard. The most
important factors are the kit itself, the precision of the
pipettes, the training and experience of the technicians,
and the linearity and repeatability of the ELISA reader.
This uncertainty of measurement has two main compo-
nents: the performance of the kit itself and the way the
test is implemented in the laboratory. The same kit
may therefore yield different uncertainties in different
laboratories.
We present here only the data generated at CIRAD.
However, the test was also performed locally elsewhere,
notably in Ethiopia, Kenya, Mali, Mauritania, Pakistan,
Senegal and Tajikistan. At all these sites, correct results
were obtained for the controls, demonstrating the ro-
bustness of the kit.
Five sites were selected for the evaluation of CCPP
seroprevalence with this cELISA (Figure 1-A). France
was selected as a representative site at which CCPP is
absent but other mycoplasmas of the mycoides cluster
are isolated frequently. The other sites selected were in
countries in which CCPP is known to occur.Seroprevalence in Central Asia
A preliminary test was performed on seven serum sam-
ples collected during a CCPP outbreak confirmed by
PCR, in South-West Tajikistan. These serum samples
were collected from goats that had shown respiratory
signs in the previous weeks or months. Six of the seven
samples tested positive and titers were very high in some
cases, with PI values of up to 90.
The 359 serum samples collected from the Wakhan
District in Afghanistan and the 199 serum samples re-
trieved from the contiguous Ishkoshim and Murghob
districts in Tajikistan tested negative. These results
are highly consistent with the absence of clinical signs
of CCPP in this part of the Central Asian highlands
(Figure 1-B).
In the province of Gilgit-Baltistan in northern
Pakistan, serological results confirmed the clinical obser-
vations suggestive of CCPP in this area, but the results
obtained differed between sampling sites. In the Gilgit
District only four of the 150 serum samples tested were
positive, giving a prevalence of 2.7% (95% CI: 0.7%-
6.7%). By contrast, in the Diamer District, 115 of the 260
serum samples tested were positive, giving a prevalence
of 44.2% (95% CI: 38.1%-50.5%), a value significantly
higher than that obtained for Gilgit. The reasons for this
difference are unknown, but further sampling, with the
testing of a larger sample spread over a broader geo-
graphical area should increase our understanding of the
variation of CCPP seroprevalence in Gilgit-Baltistan.
In the Shuro-Obod District and the contiguous Darvoz
District in southern Tajikistan, 20 of the 197 serum sam-
ples analyzed tested positive, giving a prevalence of
10.1% (95% CI: 6.3%-15.2%), confirming the clinical ob-
servations suggestive of CCPP in this region bordering
Afghanistan [20]. More precise results should become
available in the future, as a nationwide serological sur-
vey is currently being carried out as part of a tech-
nical cooperation project of the Food and Agriculture
Organization (FAO) of the United Nations. This project
should provide precise estimates of CCPP prevalence in
the Tajik goat stock.
Seroprevalence in infected African countries
and Mauritius
We tested 1000 goat serum samples from the Afar re-
gion of Ethiopia, from sites at which vaccination had
never been carried out; 146 of these samples tested posi-
tive (Figure 1-C). The individual seroprevalence in this
region was therefore 14.6% (95% CI: 13%-17%). Preva-
lence varied between sites, with values of 10 and 12%
obtained for the Dubti district and of 5.3 and 23% for
the Hadar district.
In the Narok district in Kenya (Figure 1-D), serum
samples were collected from each of the goats in 10
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which agreed to participate in the CCPP vaccination
campaign. Positive results were obtained for every herd
tested. Seroprevalence differed considerably between
herds, with between 6 and more than 90% of the serum
samples from a given herd testing positive. Herd preva-
lence may therefore be highly heterogeneous in enzootic
zones and may depend, in particular, on the time elapsed
since the start of the CCPP outbreak in the herd
concerned.
In Mauritius, only nine of the 62 herds tested positive,
with at least one serum sample having a PI value greater
than 63 (the cutoff point plus the uncertainty of meas-
urement) (Figure 1-E). Herd prevalence was therefore
estimated at about 15%, with an individual prevalence of
8%. Within the positive herds, the percentage of serum
samples testing positive was high, from 26 to 80%. In
Mauritius, it was observed that positive herds followed
animal husbandry practices favoring contact with goats
from other farms.
Detection of antibodies following vaccination
Three goats vaccinated at CIRAD with a batch of the
reference vaccine displayed rapid marked seroconver-
sion, which was detectable after as little as one week. PI
values peaked three weeks after vaccination (74, 87 and
92 respectively) and remained stable at for at least five
weeks thereafter. The same animals were retested five
months after vaccination: two continued to test positive
(PI values of 62 and 76, respectively), whereas the third
tested negative.
At AU-PANVAC, groups of two to three goats were
vaccinated with various proportions of antigen and adju-
vant. Goats vaccinated with the reference vaccine dis-
played seroconversion of a similar intensity to that seen
at CIRAD (Figure 2-A). By contrast, the use of lower
concentrations of antigen (Figure 2-C and D) and/or
adjuvant (Figure 2-B and D) resulted in seroconver-
sion that was either less pronounced or lasted for a
shorter period. The negative controls, which received
an injection of saponin alone, displayed no serocon-
version (Figure 2-E). Only one of the animals receiving
antigen alone (Figure 2-F) displayed transient serocon-
version. No seroconversion was observed in the other
two. These results confirm that the cELISA was able
to detect the antibodies induced by CCPP vaccination.
They also show that vaccine quality directly affected
the intensity and duration of seroconversion. Lower
antigen content and the use of smaller amounts of ad-
juvant resulted in weaker responses.
Discussion
This newly formatted CCPP cELISA kit performed sig-
nificantly better than the previous version. The newversion of the kit includes highly heat-stable precoated
plates in sealed packaging, and the test performs well
after incubation for three weeks at 37°C. An additional
advantage of this kit is its modification to use the same
protocol as the contagious bovine pleuropneumonia
cELISA kit (IDEXX-Montpellier SAS, France). Laboratories
that are familiar with the bovine test can therefore easily
perform the caprine test.
The very high specificity of the CCPP cELISA, at close
to 100%, was similar to that of the previous blocking
ELISA. In this study, we did not use goat herds and ani-
mals chosen at random from a CCPP-free country.
Instead, we deliberately also included goat herds infected
with other mycoplasmas of the “mycoides cluster”, to in-
crease the stringency of the test. Such animals would
probably have given cross-reactions in the less specific
complement fixation test (CFT), which uses a crude
antigen [25,26]. This cELISA can be used for the specific
detection of CCPP. Another commercially available sero-
logical test for CCPP, the latex agglutination test, is
based on the use of beads coated with Mccp polysac-
charide [27]. This test is highly suitable for the rapid
confirmation of outbreaks in the field, as agglutination is
mostly triggered by IgM antibodies. However, cELISA is
likely to be more suitable for epidemiological surveil-
lance and seroprevalence studies, as it is independent of
Ig type. Our choice of a high cutoff point, to maximize
the diagnostic specificity of the test, would be expected to
decrease diagnostic sensitivity. Further trials will certainly
be required to determine the true sensitivity of this test as
there is no gold standard serological test. Such analyses
could be achieved by the analysis of serum samples from
experimentally infected animals. The estimates of preva-
lence obtained in this study may therefore constitute an
underestimate of the true prevalence of CCPP.
The results of cELISA tests confirmed that CCPP was
enzootic in the lowlands of Kenya and Ethiopia, with a
high prevalence in the herds tested. These findings are
consistent with those of participatory enquiries [28],
which have shown that goat owners in these semi-arid
nomadic lands rank CCPP first among the threats to
their herds [7]. In Kenya, the sampled goats originated
from herds presented for vaccination. The willingness of
the owners to have their animals bled and vaccinated
may be linked to previous exposure to CCPP. Our sam-
ple cannot therefore be considered to be completely ran-
dom and the results represent no more than an estimate
of the seroprevalence of CCPP.
The epidemiological situation for CCPP in Mauritius
differs from that in East Africa. The disease was not
introduced into Mauritius until 2009, and it will be in-
teresting to follow the progress of this disease in the
coming years and to analyze it in terms of the control
strategies that may be implemented.
0
10
20
30
40
50
60
70
80
90
0 1 2 3 4 5 6
0
10
20
30
40
50
60
70
80
90
0 1 2 3 4 5 6
0
10
20
30
40
50
60
70
80
90
0 1 2 3 4 5 6
0
10
20
30
40
50
60
70
80
90
0 1 2 3 4 5 6
0
10
20
30
40
50
60
70
80
90
0 1 2 3 4 5 6
0
10
20
30
40
50
60
70
80
90
0 1 2 3 4 5 6
A B
C D
FE
Figure 2 Seroconversion, as assessed by CCPP cELISA, in goats vaccinated with various amounts of Mycoplasma capricolum subsp.
capripneumoniae antigen and saponin adjuvant. Each line represents the seroconversion of one animal. The x axis corresponds to the time in
weeks post vaccination and the y axis corresponds to the percentage inhibition values. A: Goats vaccinated with the reference vaccine (0.15 mg
antigen, 3 mg saponin), B: goats vaccinated with 0.15 mg antigen and 0.3 mg saponin, C: goats vaccinated with 0.05 mg antigen and 3 mg
saponin, D: goats vaccinated with 0.05 mg antigen and 0.3 mg saponin, E: goats receiving saponin alone (3 mg), F: goats receiving antigen
alone (0.15 mg).
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depended on the geographical origin of the samples.
These findings highlight the need for widespread sero-
logical investigations, to clarify the distribution of the dis-
ease across Asia, which is currently poorly understood.
The absence of CCPP in the Wakhan District of
North-East Afghanistan may, to some extent, reflect the
remoteness of this district, which provides some protec-
tion against the introduction of infected animals.
The high seroprevalence observed in East Africa indi-
cates a lack of success of the control strategies imple-
mented in this region, despite the local production of
CCPP vaccines. However these vaccines are difficult to
produce. This makes them expensive and limits their
use in the field.
The widespread presence of mycoplasmas of the
“mycoides cluster” around the Mediterranean basin maypotentially mask the emergence of CCPP. These myco-
plasmas induce a wide range of lesions in affected goats,
including CCPP-like pleuropneumonia. Hence, goat
owners and veterinary surgeons may not detect CCPP
quickly enough to warn local health authorities and curtail
the risk of epizootics. The cELISA may, therefore, prove
very useful for the development of epidemiological surveil-
lance activities in regions at risk of CCPP introduction,
such as the Balkans.
Finally the preliminary results obtained in this study
indicate that this serological test could be used to evalu-
ate the quality of CCPP vaccines or vaccination cam-
paigns, by monitoring the seroconversion induced in
vaccinated animals. The collection of serum samples
before vaccination and then one and two months after vac-
cination should provide clear evidence of seroconversion if
the vaccine was produced according to the OIE standards.
Peyraud et al. BMC Veterinary Research 2014, 10:48 Page 8 of 9
http://www.biomedcentral.com/1746-6148/10/48Seroconversion indicates that sufficient Mccp antigen and
adjuvant were present in the vaccine to induce the proper
response. This cELISA could therefore be used as an initial
test of potency, such tests currently being absent from the
reference quality control protocols. Further trials are re-
quired to determine whether there is a strict correlation
between antibody levels, as assessed with this cELISA, and
protection. Such trials would also be useful to determine
the true sensitivity of the test, which is difficult to evaluate
with serum samples collected in the field. Quality control
is particularly important for vaccines, as the industrial
product used is generated on a large scale and may behave
differently from the original laboratory product for which
efficacy was demonstrated [29,30]. The cELISA test could
be used, in particular, to evaluate the stability of the vaccine
in liquid form after storage at +4°C.Conclusions
The newly formatted CCPP cELISA proved to be highly
specific and robust. Localized prevalence studies con-
firmed that the prevalence of CCPP was high in the low-
lands of East Africa, where goat-rearing is a key activity
in rural communities. Prevalence studies in central Asia
showed that some regions may still be CCPP-free, whereas
others are clearly highly infected. These findings could lead
to better control strategies, including the use of cELISA for
the monitoring of vaccination campaign efficacy. Finally,
this cELISA could be used as a surveillance tool in CCPP-
free regions at risk of disease introduction, including all the
regions bordering infected zones.Ethical considerations
Goat serum samples were collected in field studies car-
ried out in various countries without ethics committees
(e.g., Tajikistan and Afghanistan). Serum sampling was
organized by the national veterinary services in accord-
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pling from the jugular vein, which is not considered to
cause any animal pain.
When CCPP vaccination was performed, notably in
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ents but at lower doses.
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